Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AB-506 is a compound that serves as an orally administered inhibitor specifically targeting the hepatitis B virus (HBV) core protein to obstruct HBV replication. It achieves this by binding to the HBV core protein, accelerating capsid assembly, and hindering the encapsidation of HBV pre-genomic RNA (pgRNA). Consequently, AB-506 is utilized in the study of chronic hepatitis B (CHB).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | AB-506 is a compound that serves as an orally administered inhibitor specifically targeting the hepatitis B virus (HBV) core protein to obstruct HBV replication. It achieves this by binding to the HBV core protein, accelerating capsid assembly, and hindering the encapsidation of HBV pre-genomic RNA (pgRNA). Consequently, AB-506 is utilized in the study of chronic hepatitis B (CHB). |
Molecular Weight | 461.85 |
Formula | C21H18ClF2N5O3 |
CAS No. | 2245020-50-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AB-506 2245020-50-0 inhibitor inhibit